Glucotrack, Inc. and Lōkahi Therapeutics™ Announce Strategic Financing Support from E.F. Hutton & Co. in Connection with Their Recently Completed Business Combination and Future Capital Markets Initiatives
GlobeNewsWire
Published: Jul 17, 2026, 09:05 PM GMT+9
Sentiment Analysis
Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), together with its operating business Lōkahi Therapeutics™ ("Lōkahi") , a clinical-stage biopharmaceutical company advancing innovative non-opioid biologic therapies and applying its proprietary ai²™ methodology to identify and develop high-value healthcare opportunities, today announced the completion of a bridge financing designed to support the Company's strategic growth objectives, including the continued advancement of the combined Glucotrack–Lōkahi platform and other anticipated capital markets activities.
The bridge financing follows the completion of the strategic business combination between Glucotrack and Lōkahi, announced on July 14, 2026 . E.F. Hutton & Co. served as exclusive financial advisor and placement agent in connection with the bridge financing and continues to support the Company as it evaluates additional financing opportunities intended to strengthen its balance sheet, advance corporate initiatives, and support long-term value creation.
"The successful completion of this bridge financing represents an important step in our broader strategic plan," said Erik Emerson, Chief Executive Officer of Glucotrack, who previously served as Chief Executive Officer of Lōkahi Therapeutics™.
"We appreciate the support and guidance of E.F. Hutton & Co. as we complete the integration of Glucotrack and Lōkahi and evaluate additional capital formation opportunities. We believe these initiatives position the Company to expand its strategic capabilities and create a stronger platform for future growth."
The bridge financing provides the Company with additional financial flexibility as it works toward completing strategic initiatives currently under evaluation. Subject to customary conditions and applicable approvals, Lōkahi intends to continue executing its strategy of identifying, evaluating, and advancing opportunities that complement its biopharmaceutical development platform and ai²™ operating model.
As part of that strategy, Lōkahi is continuing to advance the ai² Futures Lab, the first applied product of its ai² methodology. The program leverages Lōkahi’s university relationships to identify and evaluate distressed, shelved, under-prioritized, or abandoned clinical assets that may contain unrecognized strategic value, with student teams conducting structured clinical, commercial, regulatory, intellectual property, and strategic assessments before opportunities are considered for Lōkahi intake.
"We are pleased to support Lōkahi Therapeutics during this important stage of its development," said Joseph T. Rallo, Chief Executive Officer of E.F. Hutton & Co. "Lōkahi has established a differentiated strategy that combines clinical-stage biotechnology development with a disciplined approach to identifying and unlocking value from strategic opportunities, now anchored within Glucotrack's publicly listed platform. We look forward to supporting management as it executes its objectives and evaluates future financing initiatives."
Glucotrack expects to provide additional information regarding the combined company's strategic initiatives and potential financing activities as appropriate and in accordance with applicable securities laws.
About Lōkahi Therapeutics™ Lōkahi Therapeutics™ is redefining intelligent medicine—where clinical judgment, scientific rigor, and human insight guide every decision. Lōkahi is advancing non-opioid biologic therapeutic candidates and applies its proprietary ai²™ ("Actual Intelligenc...
Source: GlobeNewsWire
This content is not intended as investment advice or a recommendation. Any opinions expressed are solely the personal views of each article.